RCP Therapeutics, Ltd

RCP Therapeutics, Ltd is a regenerative medicine company focused on commercializing its proprietary nano-technologies into large markets with unmet clinical needs and improving patient outcomes.

The Company is actively developing and optimizing pioneering regenerative, curative, and preventative biomedical technologies and therapeutic products to treat and prevent human diseases. In early stage studies conducted at the Cleveland Clinic in 2008, RCP’s lead product candidate, nano SOD, demonstrated efficacy in reducing the effects of stroke and reperfusion injury.